Back to Interventions
Substance / Medication

Clofarabine

SNOMED 413873006UMLS C0092777

Overview

Active Ingredient
clofarabine
RxNorm CUI
44151

Indications

Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Labeler: Dr.Reddy's Laboratories IncUpdated: 2024-02-27T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Lymphatic leukaemia

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Recent Trials

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

NCT00361140Phase 4Completed72 enrolled

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

NCT02670564Phase 4Recruiting1000 enrolled
View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia.
Jeha Sima, Goto Hiroaki, Baruchel André et al. · Adv Ther · 2023
PMID: 37819554Meta-AnalysisFull text (PMC)
Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.
Hermans Sjoerd J F, van Norden Yvette, Versluis Jurjen et al. · Cancer Med · 2024
PMID: 38680089RCTFull text (PMC)
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Russell Nigel H, Hills Robert K, Kjeldsen Lars et al. · Br J Haematol · 2022
PMID: 35388465RCT
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Rijneveld Anita W, van der Holt Bronno, de Weerdt Okke et al. · Blood Adv · 2022
PMID: 34883506RCTFull text (PMC)
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Escherich Gabriele, Zur Stadt Udo, Borkhardt Arndt et al. · Haematologica · 2022
PMID: 34348455RCTFull text (PMC)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg Bob, Pabst Thomas, Maertens Johan et al. · Blood · 2017
PMID: 28049642RCT
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Faderl Stefan, Garcia-Manero Guillermo, Jabbour Elias et al. · Cancer · 2012
PMID: 21751197RCTFull text (PMC)
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson Borje S, Valdez Benigno C, de Lima Marcos et al. · Biol Blood Marrow Transplant · 2011
PMID: 20946966RCTFull text (PMC)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl Stefan, Ravandi Farhad, Huang Xuelin et al. · Blood · 2008
PMID: 18565853RCTFull text (PMC)
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.
Jullien Maxime, Brissot Eolia, Daguindau Etienne et al. · Bone Marrow Transplant · 2025
PMID: 40954245Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Clofarabine (substance)
SNOMED CT
413873006
UMLS CUI
C0092777
RxNorm CUI
44151
Labeler
Dr.Reddy's Laboratories Inc

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.